Overview

A Study of CN202 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies

Status:
Not yet recruiting

Trial end date:
2023-10-06

Target enrollment:

Participant gender:

Summary

The study is designed to evaluate the safety, tolerability, pharmacokinetic characteristics and anti-tumor activity of CN202 in adult subjects with locally advanced or metastatic solid tumor or hematologic malignancies

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Curon Biopharmaceutical (Australia) Co Pty Ltd

Collaborator:

Novotech (Australia) Pty Limited